biostudies-literatureUnknownHingrat QLMinistry of HealthPfizerInsermHologicSanofi PasteurBMSBeckton DickinsonBiomerieuxQiagenViiV HealthcareAbbvieANRSREACTingMedimuneDa VolterraJ&amp;JMylanAAZTheratechnologieGileadBioMérieuxGilead SciencesMSD<h4>Objectives</h4>Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19 diagnostic. The high technicalities of nasopharyngeal sampling and molecular assays, as well as scarce resources of reagents, limit our testing capabilities. Several strategies failed, to date, to fully alleviate this testing process (e.g. saliva sampling or antigen testing on nasopharyngeal samples). We assessed the clinical performances of SARS-CoV-2 nucleocapsid antigen (N-antigen) ELISA detection in serum or plasma using the COVID-19 Quantigene® (AAZ, France) assay.<h4>Methods</h4>Performances were determined on 63 sera from 63 non-COVID patients and 227 serum samples (165 patients) from the French COVID and CoV-CONTACT cohorts with RT-PCR confirmed SARS-CoV-2 infection, including 142 serum (Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious DiseasesS1198-743X(20)30721-7https://www.ebi.ac.uk/biostudies/studies/S-EPMC7724284biostudies-literatureDetection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.PMC772428420-0424Bompart FEric CTCharline VJohn KShana AInsermZaven TMouquet HBernard TFlorence DAmelie LDa Silveira CKaguelidou FThu Huong DTQuentin LTellier MCMaria-Claire MEstelle LBeluze Mmembers of the French-COVID cohort study group (by alphabetical order)Soumaya OLevy YAline DFanny ALuc CJCoV-CONTACT Clinical CentersCoelho ATimsit JFMarilou BA JMichel DJMohammed NSLe Mestre SSemaille CLingas GDubos FVirginie CKevin BValentine PCatherine CDouae AKhadija ABenkerrou DDebray MPBehilill SThierry RFrederique BCatherine MHelene EThierry PAgnes CHelene JTagherset LCatherine SSolene MQLea BMaxime DHelene BAdeline PMaud BEnouf VTual CPeytavin GTubiana SRoy CAngoulvant FSteering CommitteePartnersDuval XFrance MJulie FDuc NSandrine SLucet JCJustina MSandrine TPapadopoulos ACecile RVeislinger ASandrine AEmmanuelle KDamond FSandrine GEnkelejda HJean-Luc EPaul CEmmanuelle MCervantes-Gonzalez MWahiba FAndreea PDidier HBertine MPuechal OFrancis GEmila IHAbel LCedric HAlexandra MWerf Sylvie VNathalie PCedric LNabil BEsperou HPierre AAlexandra RVristi DNathalie GSarah TNawal WGuillaume LMWiedemann AKhalil AMambert MTerrier OJean-Christophe LChair ABiological CenterBachelet DHulot JSEsposito-Farese MTeoule FNeant NAnne TYolande CAnne SAnne LDavid LOuifiya KBenoit VKarline ATMercier NAstrid VStephane DDescamps DSponsorStephane PChoquet CVisseaux BBhavsar KLysiane BGault NBouscambert MXavier DEttalhaoui NMayka MFSylvie CChristophe PElise RGSylvie BJaafoura SClaire LEloy PBeatrice HBurdet CDorival CPatrick GLe Hingrat QPatrick RClaire CCeline GLaouenan CSoizic LD'ortenzio EPetrov-Sanchez VLucas PSolange NHingrat QLCarole LSamia HBetty SEric LSandrine CCElise ENathan PSTardivon CCouffignal CGigante THoffmann IMaider PEric CDesvallee MMarie DGeneticBasmaci RSeverine LCoordination and statistical analysesNoret MAude LMaelle DGaymard ACharles BVirological LabCharpentier CCouffin-Cardiergues SManchon PElisabeth BNMikael ASophie LKali SLaurence GMireille DDLoubna AKarine LSophie GLescure FXSchneider MDalila LYazdanpanah YNolwenn BLevy-Marchal CKhaly SHoctin ARenaud VKafif OWilliam FIchou HLe Nagard HDiouf APeiffer-Smadja NVan Der Werf SKarine AValerie VVanel NMichael TDenis MChristelle DJade RChristine PChristelle KGorenne IMullaert JPauline MDeplanque DCaroline DChirouze CLina BJean-Sebastien AIsabelle MPauline VDiallo APauline PPages JDer Werf Sylvie VRosa-Calatrava MBruno CLe MQuentin LHEmilie GCaroline QMeziane AAndrejak CMilica MMalvy DBouadma LRossignol PTrioux TAlexandre MBruno LBruno MMarie GBenmalek NHouas IRossignol BEtienne MFabrice LStephanie SNadhira HGilg MMentre FAdrien MMathilde BFrench COVID cohort management committee, CoV-CONTACT study groupLaribi SMarion DMaty KViviane FMarion BJonathan LHouhou-Fidouh NNicolas EThiphaine VLayide Rmember of the CoV-CONTACT study group. Principal investigatorPicone OBenjamin LNicolas LDianes DCharlotte CMohamed MKhan CValerie GFelix DGhosn JGuedj JDominique DSophie CZDominique AfalseDetection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.<h4>Objectives</h4>Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19 diagnostic. The high technicalities of nasopharyngeal sampling and molecular assays, as well as scarce resources of reagents, limit our testing capabilities. Several strategies failed, to date, to fully alleviate this testing process (e.g. saliva sampling or antigen testing on nasopharyngeal samples). We assessed the clinical performances of SARS-CoV-2 nucleocapsid antigen (N-antigen) ELISA detection in serum or plasma using the COVID-19 Quantigene® (AAZ, France) assay.<h4>Methods</h4>Performances were determined on 63 sera from 63 non-COVID patients and 227 serum samples (165 patients) from the French COVID and CoV-CONTACT cohorts with RT-PCR confirmed SARS-CoV-2 infection, including 142 serum (2020-01-01T00:00:00Z2020 Dec2026-05-04T22:49:20.571Z2021-02-20T16:49:29ZS-EPMC77242843330722710.1016/j.cmi.2020.11.025